Literature DB >> 9427779

Enhanced expression of metallothionein in human non-small-cell lung carcinomas following chemotherapy.

Y Matsumoto1, M Oka, A Sakamoto, F Narasaki, M Fukuda, H Takatani, K Terashi, K Ikeda, J Tsurutani, S Nagashima, H Soda, S Kohno.   

Abstract

Metallothioneins (MTs) are induced by various stimuli and probably confer drug resistance in tumor cells in vitro. To investigate whether MT expression in lung cancer is induced by chemotherapy, ninety-seven surgical specimens from patients who had or not received chemotherapy containing cisplatin, were stained immunohistochemically for MT. In untreated tumors, 23% (15/64) of all tumors and 27% (15/56) of non-small-cell carcinoma (NSCLC) stained positive, while all eight small-cell carcinoma (SCLC) were negative. In treated tumors, 52% (17/33) of all tumors, 80% (12/15) of NSCLC and 28% (5/18) of SCLC stained positive. The proportion of positively-stained tumors was significantly higher in treated NSCLC compared with untreated NSCLC (P = 0.0005) and treated SCLC (P < 0.005). Our results indicate that MT expression increases following chemotherapy and that such expression may confer during resistance in lung cancer, especially NSCLC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427779

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

2.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

Review 3.  The roles of metallothioneins in carcinogenesis.

Authors:  Manfei Si; Jinghe Lang
Journal:  J Hematol Oncol       Date:  2018-08-23       Impact factor: 17.388

4.  The reversal of drug resistance by two-dimensional titanium carbide Ti2 C (2D Ti2C) in non-small-cell lung cancer via the depletion of intracellular antioxidant reserves.

Authors:  Yue Zhu; Baiyan Sui; Xin Liu; Jiao Sun
Journal:  Thorac Cancer       Date:  2021-11-05       Impact factor: 3.500

5.  Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer.

Authors:  Khurum Khan; Gerard G Hanna; Lynn Campbell; Paula Scullin; Adnan Hussain; Ruth L Eakin; Jonathan McAleese
Journal:  Chin J Cancer       Date:  2013-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.